title: [A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC)].
abstract: A 66-year-old woman was seen at our hospital because of abdominal fullness. A computed tomography(CT)revealed massive tumors in abdominal cavity. The patient underwent surgery consisting of tumorectomy, segmental gastrectomy, partial resection of small intestin, transverse colectomy, left oophorectomy and gastrostomy. By using immunohistochemical staining, the patient was diagnosed as sarcomatoid malignant peritoneal mesothelioma. Rapidly abdominal fullness occurred as of 22 days after the operation, and an abdominal CT revealed the massive recurrent tumors. We started a combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine (CYVADIC). The recurrent tumors showed remarkable reduction after the two courses of CYVADIC chemotherapy. Although we next started carboplatin and paclitaxel combination chemotherapy, she died due to rapidly progression of the disease with disseminated intravascular coagulation after 132 days of the operation. Malignant mesothelioma, especially sarcomatoid mesothelioma, is known to have a poor prognosis. However, our case suggests that we could improve the prognosis of sarcomatoid malignant mesothelioma by aggressive chemotherapy.
authors.affiliation: Dept. of Hematology and Oncology, Kobe University Graduate School of Medicine.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kusama
authors.forename: Taiichi
authors.initials: T
authors.lastname: Kodaka
authors.forename: Hiroko
authors.initials: H
authors.lastname: Tsunemine
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Akasaka
authors.forename: Naoki
authors.initials: N
authors.lastname: Koizumi
authors.forename: Koji
authors.initials: K
authors.lastname: Fujimoto
authors.forename: Shigeru
authors.initials: S
authors.lastname: Sakano
authors.forename: Rieko
authors.initials: R
authors.lastname: Ito
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Sohei
authors.initials: S
authors.lastname: Kitazawa
authors.forename: Hisako
authors.initials: H
authors.lastname: Yamamura
authors.forename: Katsuhito
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008654:Mesothelioma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide